Aliri identifies the causes of toxicology with molecular histology

 

Aliri is revolutionizing the way we identify the causes of toxicology through advanced molecular histology. With our cutting-edge Multimaginging technology, we can directly correlate the molecular distribution of targeted molecules to histopathological and functional tissue changes. Download our fact sheet to learn more about how Aliri can transform your toxicology studies.

Download Now

LC/MS/MS Analysis of Coproporphyrin I and Coproporphyrin III in Human Plasma

 

A bioanalytical assay was developed and validated for the analysis of coproporphyrin I (CP‐I) and coproporphyrin III (CP‐III) in human plasma to assess hepatic OATP1B1/1B3 function. This method uses LC-MS/MS detection to monitor these biomarkers and potentially avoid the need for dedicated clinical drug-drug interaction studies. Download our poster to learn more.

Download Now

NPA List

 

Aliri brings more than 30 years of experience in bioanalytical services, developing robust methods to support all stages of drug discovery and development.  We offer an extensive list of validated, off-the-shelf assays you can leverage to support a range of research applications.  In addition to the hundreds of assays listed below, Aliri also excels at developing customized methods to meet your specific challenges.

Download Now

The Importance of Sample Clean up Demonstrated by the Revalidation of the Biomarker 4β-hydroxycholesterol for Assay Robustness

 

Uncover the advancements reshaping biomarker analysis with our refined method for quantifying 4β-hydroxycholesterol (4β-OHC) – a vital biomarker for CYP3A activity. With our improved assay methodology, we offer a reliable solution for quantifying 4β-OHC, empowering researchers and clinicians with accurate biomarker data for informed treatment decisions.

Download our poster to unlock the potential of this innovative approach.

Download Now

Validation of an LCMS Hybrid Assay with EVOSEP cleanup for the quantitation of Islet Amyloid polypeptide in human plasma

 

Delve into the forefront of biomarker analysis with our validated LCMS Hybrid Assay, offering precise quantitation of Islet Amyloid Polypeptide (IAPP) in human plasma. Our method revolutionizes detection by coupling immunoprecipitation from plasma with EVOSEP solid phase extraction and microflow chromatography, resulting in detection limits comparable to traditional methods. By leveraging a high-binding, non-specific antibody for IAPP, our assay surpasses commercially available kits, ensuring comprehensive analysis of different IAPP forms.

Download our poster to discover the innovation behind our approach and its potential uses in regulated settings and biologics advancement.

Download Now

Tissue Adenosine Distribution-Guided Gene Selection for the Development of a Composite Biomarker in Immuno-Oncology Therapy

 

Discover the groundbreaking approach revolutionizing Immuno-Oncology (IO) therapy through tissue adenosine distribution-guided gene selection for composite biomarker development. Our method transcends traditional predictive biomarkers by integrating spatial metabolomics and genomics, offering a comprehensive strategy to predict patient responses to IO therapies.

Download our poster to explore the transformative potential of adenosine-driven gene signatures in personalized cancer treatment strategies.

Download Now

Multimodal stratification of predictive biomarkers in head and neck cancers: A focus on cytokine-based immunotherapy

 

Explore our recent poster presentation, which discusses the challenge of identifying predictive biomarkers for cytokine-based immunotherapy in head and neck cancers due to the complexity of biological systems and cancer pathophysiology. It highlights the importance of understanding how drugs interact with different biomarkers and tissues spatially to improve trial success rates, reduce costs, and accelerate completion times.

By analyzing spatial and temporal changes in tumor cells and their microenvironment, you can uncover resistance mechanisms, leading to the design of more effective combination therapies. The Aliri solution offers enhanced tumor profiling through spatial analysis, integration of heterogenous data types, and predictive analysis, ultimately identify robust biomarker signatures for improved immunotherapy outcomes.

Download our poster to gain insights into the unique biomarker signatures correlated with therapy response.

Download Now

Keeping an eye on molecular imaging: drug efficacy & toxicity in ophthalmology

 

Discover how Mass Spectrometry Imaging (MSI) is revolutionizing preclinical studies by offering quick and accurate assessments of ocular treatments’ efficacy and safety.

With MSI, track the bio-distribution of drugs and metabolites while pinpointing biomarkers for efficacy or toxicity. Gain valuable insights into ocular drug distribution and biomarker modulation with Aliri’s advanced MSI technology.

Download our application note to dive deeper into our MSI technology and its applications in ocular diseases.

Download Now

Coproporphyrin-I and Coproporphyrin-III

 

Aliri Bioanalysis presents a newly validated non-proprietary biomarker assay (NPA) for the quantitation of Coproporphyrin I and Coproporphyrin III in human plasma. This assay offers significant advancements in biomarker analysis, applicable across diagnostics, pharmaceutical research, and patient care.

By monitoring these biomarkers, particularly in early clinical development, companies can assess OATP1B1 inhibition, potentially avoiding the need for dedicated clinical drug-drug interaction studies, saving both time and money.

Learn more about the benefits of our NPA for Coproporphyrin I and Coproporphyrin III.

Download Now

Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRAS G12C , are associated with renal toxicity in the Sprague Dawley rat

 

Sotorasib is a first-in class KRAS G12C covalent inhibitor in clinical development for the treatment of tumors with
the KRAS p.G12C mutation. In the nonclinical toxicology studies of sotorasib, the kidney was identified as a
target organ of toxicity in the rat but not the dog. Renal toxicity was characterized by degeneration and necrosis
of the proximal tubular epithelium localized to the outer stripe of the outer medulla (OSOM), which suggested
that renal metabolism was involved. Here, we describe an in vivo mechanistic rat study designed to investigate
the time course of the renal toxicity and sotorasib metabolites. Renal toxicity was dose- and time-dependent,
restricted to the OSOM, and the morphologic features progressed from vacuolation and necrosis to regeneration
of tubular epithelium. The renal toxicity correlated with increases in renal biomarkers of tubular injury.
Using mass spectrometry and matrix-assisted laser desorption/ionization, a strong temporal and spatial associ –
ation between renal toxicity and mercapturate pathway metabolites was observed. The rat is reported to be
particularly susceptible to the formation of nephrotoxic metabolites via this pathway. Taken together, the data
presented here and the literature support the hypothesis that sotorasib-related renal toxicity is mediated by a
toxic metabolite derived from the mercapturate and B-lyase pathway. Our understanding of the etiology of the rat
specific renal toxicity informs the translational risk assessment for patients.

Download Now